Medical Properties (MPW) closed the most recent trading day at $4.52, making no change from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.55% for the day. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.63%. The health care real estate investment trust's shares have seen a decrease of 6.42% over the last month, not keeping up with the Finance sector's loss of 2.67% and the S&P 500's gain of 4.28%. Analysts and investors alike will be keeping a close eye on the performance of Medical Properties in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.21, showcasing a 56.25% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $251.2 million, down 25.55% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $0.87 per share and a revenue of $1 billion, demonstrating changes of -45.28% and +14.98%, respectively, from the preceding year. Any recent changes to analyst estimates for Medical Properties should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Medical Properties is currently sporting a Zacks Rank of #5 (Strong Sell). Digging into valuation, Medical Properties currently has a Forward P/E ratio of 5.18. This valuation marks a discount compared to its industry's average Forward P/E of 12.23. We can also see that MPW currently has a PEG ratio of 0.65. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the REIT and Equity Trust - Other industry had an average PEG ratio of 2.33. The REIT and Equity Trust - Other industry is part of the Finance sector. With its current Zacks Industry Rank of 179, this industry ranks in the bottom 29% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medical Properties Trust, Inc. (MPW):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Medical Properties (MPW) Flat As Market Gains: What You Should Know
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...